Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma
The objective of this study is to evaluate the efficacity of the combination of cisplatin-5-FU and docetaxel in adapted doses in term of response to treatment without toxicity

.
Cancer of Head and Neck
DRUG: Docetaxel|DRUG: Cisplatin|DRUG: Fluoro Uracil
Efficacity of combination of TPFm, Success rate of patients at 8 weeks, 8 weeks after the end of treatment
Overall survival, The time from date of randomization to date of death due to any cause, 3 months after the end of treatment|Progression free survival, The time from date randomization to date of first evidence of progression, 3 months after the end of treatment|incidence of local and/or locor√©gional failure, 3 months after the end of treatment|Laryngeal preservation, 3 months after the end of treatment|incidence of distant metastatic failure, The time from the date of randomization and the date of first evidence of metastatic progression, or the date of death, whatever the cause, 3 months after the end of treatment|Toxicities of complementary treatment to induction tretatment, Rate of patients who received the whole of complementary treatment, 3 months after the end of treatment|QLQ-C30 questionnaires, These questionnaires assess the impact of the desease and treatment on tthe patient's life, 8 weeks, 6 months (3 months after the end of treatment) and 24 months after the end of treatment|QLQ-H&N35 questionnaires, These questionnaires assess the impact of the desease and treatment on tthe patient's life, 8 weeks, 6 months (3 months after the end of treatment) and 24 months after the end of treatment
After explaining the treatment modalities, having read and explained the information letter to them, patients who have signed the consent to participate in the trial and who meet the inclusion criteria will be enrolled and randomized in the trial .